Anti-CD38 antibody therapy: Windows of opportunity yielded by the functional characteristics of the target molecule

Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 99-108

  Chillemi, Antonella ^a   Zaccarello, Gianluca ^a   Quarona, Valeria ^a   Ferracin, Manuela ^b   Ghimenti, Chiara ^c   Massaia, Massimo ^a,d   Horenstein, Alberto L ^a   Malavasi, Fabio ^a,e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c Laboratory of Cancer Genomics   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; DARATUMUMAB; MICRORNA; RETINOIC ACID; STEM CELL FACTOR RECEPTOR; TAMIBAROTENE;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CD38 GENE; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; DRUG SCREENING; HUMAN; IMMUNOPHENOTYPING; IN VIVO STUDY; LEUKEMIA CELL; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTIPLE MYELOMA;

EID: 84878200023     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2013.00009     Document Type: Review

References (69)

1. Maecker HT, McCoy JP, Nussenblatt R. (2012) Standardizing immunophenotyping for the Human Immunology Project. Nat. Rev. Immunol. 12:191-200
2. Alessio M, et al. (1990) CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells. J. Immunol. 145:878-884
3. Mallone R, et al. (1998) Characterization of a CD38-like 78-kilodalton soluble protein released from B cell lines derived from patients with Xlinked agammaglobulinemia. J. Clin. Invest. 101:2821-2830
4. Hara-Yokoyama M, et al. (2012) Tetrameric interaction of the ectoenzyme CD38 on the cell surface enables its catalytic and raft-association activities. Structure. 20:1585-1595
5. Zhao YJ, Lam CM, Lee HC. (2012) The membrane- bound enzyme CD38 exists in two opposing orientations. Sci. Signal. 5:RA67
6. Funaro A, et al. (1990) Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J. Immunol. 145:2390-2396
7. Terhorst C, et al. (1981) Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell. 23:771-780
8. Fedele G, et al. (2004) CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur. J. Immunol. 34:1342-1350
9. Buggins AG, et al. (2010) Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NFkappaB activation and de novo gene transcription. Cancer Res. 70:7523-7533
10. Ausiello CM, Urbani F, la Sala A, Funaro A, Malavasi F. (1995) CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes. Eur. J. Immunol. 25:1477-1480
11. Deaglio S, et al. (1998) Human CD38 (ADPribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J. Immunol. 160:395-402
12. Horenstein AL, Stockinger H, Imhof BA, Malavasi F. (1998) CD38 binding to human myeloid cells is mediated by mouse and human CD31. Biochem. J. 330 (Pt 3):1129-1135
13. Liu Q, et al. (2005) Crystal structure of human CD38 extracellular domain. Structure. 13:1331-1339
14. Malavasi F, et al. (2008) Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev. 88:841-886
15. Funaro A, et al. (1996) Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. Int. Immunol. 8:1643-1650
16. Zumaquero E, et al. (2010) Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with signaling complexes containing CD81, Hsc-70 and Lyn. Exp. Cell. Res. 316:2692-2706
17. Damle RN, et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94:1840-1847
18. Chiorazzi N. (2012) Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am. Soc. Hematol. Educ. Program. 2012:76-87
19. Malavasi F, et al. (2011) CD38 and chronic lymphocytic leukemia: a decade later. Blood. 118:3470-3478
20. Funaro A, et al. (1998) CD38 functions are regulated through an internalization step. J. Immunol. 160:2238-2247
21. Dianzani U, Malavasi F. (1995) Lymphocyte adhesion to endothelium. Crit. Rev. Immunol. 15:167-200
22. Newman PJ. (1999) Switched at birth: a new family for PECAM-1. J. Clin. Invest. 103:5-9
23. Deaglio S, et al. (1996) Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. J. Immunol. 156:727-734
24. Deaglio S, et al. (2000) CD38/CD31, a receptor/ ligand system ruling adhesion and signaling in human leukocytes. Chem. Immunol. 75:99-120
25. Deaglio S, et al. (2007) CD38/CD19: a lipid raftdependent signaling complex in human B cells. Blood. 109:5390-5398
26. Hu H, Li S, Liu J, Ni B. (2012) MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells. Acta Biochim. Biophys. Sin. (Shanghai). 44:424-430
27. Chen J, et al. (2010) MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol. 176:2520-2529
28. Rauhala HE, et al. (2010) MiR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int. J. Cancer. 127:1363-1372
29. Li XF, Yan PJ, Shao ZM. (2009) Downregulation of miR-193b contributes to enhance urokinasetype plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene. 28:3937-3948
30. Xu C, et al. (2010) MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur. J. Cancer. 46:2828-2836
31. Gao XN, et al. (2011) MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk. Res. 35:1226-1232
32. Unno K, Zhou Y, Zimmerman T, Platanias LC, Wickrema A. (2009) Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk. Lymphoma. 50:1865-1871
33. Cirera-Salinas D, et al. (2012) Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle. 11:922-33
34. Najafi-Shoushtari SH, et al. (2010) MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 328:1566-1569
35. Wu ZS, et al. (2011) MiR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer. 117:2842-2852
36. Deaglio S, et al. (2010) CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol. Med. 16:87-91
37. Ferrero E, Saccucci F, Malavasi F. (1999) The human CD38 gene: polymorphism, CpG island, and linkage to the CD157 (BST-1) gene. Immunogenetics. 49:597-604
38. Drach J, et al. (1994) Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. Cancer Res. 54:1746-1752
39. Aggarwal S, et al. (2006) Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol. Biol. Cell. 17:566-575
40. Uruno A, et al. (2011) All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta. J. Leukoc. Biol. 90:235-247
41. Le May N, et al. (2012) Poly (adp-ribose) glycohydrolase regulates retinoic acid receptor-mediated gene expression. Mol. Cell. 48:785-798
42. Howard M, et al. (1993) Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 262:1056-1059
43. Kim H, Jacobson EL, Jacobson MK. (1993) Synthesis and degradation of cyclic ADP-ribose by NAD glycohydrolases. Science. 261:1330-1333
44. Zocchi E, Franco L, Guida L, Calder L, De Flora A. (1995) Self-aggregation of purified and membrane- bound erythrocyte CD38 induces extensive decrease of its ADP-ribosyl cyclase activity. FEBS Lett. 359:35-40
45. Takasawa S, et al. (1993) Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. J. Biol. Chem. 268:26052-4
46. Aarhus R, Graeff RM, Dickey DM, Walseth TF, Lee HC. (1995) ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J. Biol. Chem. 270:30327-30333
47. Guse AH, et al. (1999) Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature. 398:70-73
48. Morra M, Zubiaur M, Terhorst C, Sancho J, Malavasi F. (1998) CD38 is functionally dependent on the TCR/CD3 complex in human T cells. FASEB J. 12:581-592
49. Takasawa S, Nata K, Yonekura H, Okamoto H. (1993) Cyclic ADP-ribose in insulin secretion from pancreatic beta cells. Science. 259:370-373
50. Malavasi F, et al. (2010) The hidden life of NAD+- consuming ectoenzymes in the endocrine system. J. Mol. Endocrinol. 45:183-191
51. Hubert S, et al. (2010) Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J. Exp. Med. 207:2561-2568
52. Chiarugi A, Dolle C, Felici R, Ziegler M. (2012) The NAD metabolome-a key determinant of cancer cell biology. Nat. Rev. Cancer. 12:741-752
53. Katada T, et al. (2000) Enzymic and signal transduction properties of CD38/NADase and PC-1/ phosphodiesterase. Chem. Immunol. 75:60-78
54. Goding JW, et al. (1998) Ecto-phosphodiesterase/ pyrophosphatase of lymphocytes and nonlymphoid cells: structure and function of the PC- 1 family. Immunol. Rev. 161:11-26
55. Serra S, et al. (2011) CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood. 118:6141-6152
56. Giuliani N, et al. (2012) Increased osteocyte death in multiple myeloma patients: Role in myeloma-induced osteoclast formation. Leukemia. 26:1391-1401
57. Flemming A. (2012) Deal watch: J&J and Genmab deal to push forward CD38 as a blood cancer target. Nat. Rev. Drug Discov. 11:822
58. Verfaillie CM, Miller JS. (1994) CD34+/CD33- cells reselected from macrophage inflammatory protein 1 alpha+interleukin-3-supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture initiating cells. Blood. 84:1442-1449
59. Horenstein AL, et al. (2009) CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. Mol. Med. 15:76-84
60. Lane D. (2006) Designer combination therapy for cancer. Nat. Biotechnol. 24:163-164
61. Gennarino VA, et al. (2012) Identification of microRNA-regulated gene networks by expression analysis of target genes. Genome Res. 22:1163-1172
62. Saborit-Villarroya I, et al. (2011) E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. Leukemia. 25:479-488
63. Bahri R, Bollinger A, Bollinger T, Orinska Z, Bulfone-Paus S. (2012) Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-gamma-mediated suppressor activities. PLoS One. 7:e45234
64. Zhang B. (2012) CD73 promotes tumor growth and metastasis. Oncoimmunology. 1:67-70
65. Stagg J. (2012) The double-edge sword effect of anti-CD73 cancer therapy. Oncoimmunology. 1:217-218
66. Pegoraro L, et al. (1989) The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood. 73:1020-1027
67. Quarona V, et al. (2013) CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin. Cytom. 2013, Apr 10. [Epub ahead of print].
68. Scatolini M, et al. (2010) Altered molecular pathways in melanocytic lesions. Int. J. Cancer. 126:1869-1881
69. Ferracin M, et al. (2011) MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J. Pathol. 225:43-53.